These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24960209)

  • 21. Synthesis and evaluation in rats of the dopamine D2/3 receptor agonist 18F-AMC20 as a potential radioligand for PET.
    Shalgunov V; van Wieringen JP; Janssen HM; Fransen PM; Dierckx RA; Michel MC; Booij J; Elsinga PH
    J Nucl Med; 2015 Jan; 56(1):133-9. PubMed ID: 25476538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A bibenzyl compound 20C protects rats against 6-OHDA-induced damage by regulating adaptive immunity associated molecules.
    Wang S; Han QW; Zhou TT; Zhang CL; Zhu CG; Zhou X; Chen NH; Yuan YH; Shi JG
    Int Immunopharmacol; 2021 Feb; 91():107269. PubMed ID: 33340781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: parallel observations from co-transfected human and native cerebral receptors.
    Aloisi G; Silvano E; Rossi M; Millan MJ; Maggio R
    Neuropharmacology; 2011; 60(2-3):439-45. PubMed ID: 21035472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models.
    Jeon MY; Lee WY; Kang HY; Chung EJ
    Neurol Res; 2007 Apr; 29(3):289-95. PubMed ID: 17509229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In Vitro and In Vivo Identification of Novel Positive Allosteric Modulators of the Human Dopamine D2 and D3 Receptor.
    Wood M; Ates A; Andre VM; Michel A; Barnaby R; Gillard M
    Mol Pharmacol; 2016 Feb; 89(2):303-12. PubMed ID: 26655303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.
    Kumar R; Riddle LR; Griffin SA; Chu W; Vangveravong S; Neisewander J; Mach RH; Luedtke RR
    Neuropharmacology; 2009; 56(6-7):956-69. PubMed ID: 19371586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bivalent dopamine agonists with co-operative binding and functional activities at dopamine D2 receptors, modulate aggregation and toxicity of alpha synuclein protein.
    Dinda B; Das B; Biswas S; Sharma H; Armstrong C; Yedlapudi D; Antonio T; Reith M; Dutta AK
    Bioorg Med Chem; 2023 Jan; 78():117131. PubMed ID: 36571976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reinforcing properties of Pramipexole in normal and parkinsonian rats.
    Engeln M; Ahmed SH; Vouillac C; Tison F; Bezard E; Fernagut PO
    Neurobiol Dis; 2013 Jan; 49():79-86. PubMed ID: 22940424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
    Jalewa J; Sharma MK; Gengler S; Hölscher C
    Neuropharmacology; 2017 May; 117():238-248. PubMed ID: 28223210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptors.
    Gopishetty B; Zhang S; Kharkar PS; Antonio T; Reith M; Dutta AK
    Bioorg Med Chem; 2013 Jun; 21(11):3164-74. PubMed ID: 23623679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease.
    Zhang Y; Wu Q; Zhang L; Wang Q; Yang Z; Liu J; Feng L
    Pharmacol Res; 2019 Dec; 150():104538. PubMed ID: 31707034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metformin lowers α-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson's disease.
    Katila N; Bhurtel S; Shadfar S; Srivastav S; Neupane S; Ojha U; Jeong GS; Choi DY
    Neuropharmacology; 2017 Oct; 125():396-407. PubMed ID: 28807678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
    Chiu WH; Carlsson T; Depboylu C; Höglinger GU; Oertel WH; Ries V
    Neuropharmacology; 2014 Apr; 79():212-21. PubMed ID: 24291466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Squamosamide derivative FLZ protected dopaminergic neuron by activating Akt signaling pathway in 6-OHDA-induced in vivo and in vitro Parkinson's disease models.
    Bao XQ; Kong XC; Kong LB; Wu LY; Sun H; Zhang D
    Brain Res; 2014 Feb; 1547():49-57. PubMed ID: 24384139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
    Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
    Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.
    Atack JR; Shook BC; Rassnick S; Jackson PF; Rhodes K; Drinkenburg WH; Ahnaou A; Te Riele P; Langlois X; Hrupka B; De Haes P; Hendrickx H; Aerts N; Hens K; Wellens A; Vermeire J; Megens AA
    ACS Chem Neurosci; 2014 Oct; 5(10):1005-19. PubMed ID: 25203719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin.
    Li C; Biswas S; Li X; Dutta AK; Le W
    J Neurosci Res; 2010 Aug; 88(11):2513-23. PubMed ID: 20623619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease.
    Scheller D; Ullmer C; Berkels R; Gwarek M; Lübbert H
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Jan; 379(1):73-86. PubMed ID: 18704368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
    Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
    Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.